Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion

Autor:	Cynthia Matossian, Jennifer Loh, William Trattler
Rok vydání:	2021
Předmět:	medicine.medical_specialty Corneal staining immunosuppressive agent DED genetic structures business.industry Clinical Ophthalmology Signs and symptoms Klarity-C cyclosporine 0.1% dry eye disease eye diseases Ophthalmology chemistry.chemical_compound dry eye treatment Multicenter study chemistry Medicine Ocular Surface Disease Index sense organs Chondroitin sulfate business Adverse effect Original Research
Zdroj:	Clinical Ophthalmology (Auckland, N.Z.)
ISSN:	1177-5483
Popis:	Cynthia Matossian,1 William Trattler,2 Jennifer Loh3 1Matossian Eye Associates, Pennington, NJ, USA; 2Center for Excellence in Eye Care, Miami, FL, USA; 3Loh Ophthalmology Associates, Miami, FL, USACorrespondence: Cynthia MatossianMatossian Eye Associates, 2 Capital Way, Ste 326, Pennington, NJ, 08534, USATel +1 215-230-9200Email cmatossian@cmassociatesllc.netPurpose: To evaluate the efficacy of topical cyclosporine 0.1% in chondroitin sulfate emulsion for the treatment of dry eye.Methods: This retrospective multicenter study included 100 eyes of 50 dry eye patients aged ≥ 18 years, with preoperative ocular surface disease index (OSDI) score > 12 or corneal staining grade > 1 (in either eye) who underwent dry eye treatment with topical cyclosporine 0.1% in chondroitin sulfate emulsion (Klarity-C, ImprimisRx) for 3 months. Postoperative evaluation included comparison of the changes in OSDI score and corneal staining grade after 3 months of treatment from baseline.Results: From baseline to 3 months, a statistically significant improvement in mean OSDI scores (38.19 vs 24.18, p < 0.001) as well as mean corneal staining grade (3.62 vs 2.20, p < 0.001) was observed. The proportion of subjects with severe dry eye decreased from 62% to 20% and more than one-third (34%) of patients were in the normal OSDI range. The percentage of eyes with corneal staining grade of 2 or 3 decreased from 21% (baseline) to 8% at 3 months; 50% of the eyes had corneal staining grade of 0. The treatment was found to be safe with no adverse events observed in the study.Conclusion: Dry eye treatment with twice daily cyclosporine 0.1% in chondroitin sulfate emulsion was found to be safe and effective in reducing signs and symptoms of dry eye.Keywords: dry eye treatment, dry eye disease, cyclosporine 0.1%, Klarity-C, immunosuppressive agent DED
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae77d68db1a7f03fece89b63ea174a6 https://doi.org/10.2147/opth.s308088 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.